Protalix BioTherapeutics, Inc. (PLX)
- Previous Close
3.0000 - Open
3.0300 - Bid 3.0300 x 1000
- Ask 3.0400 x 1800
- Day's Range
2.9450 - 3.0750 - 52 Week Range
0.8200 - 3.1000 - Volume
530,888 - Avg. Volume
728,567 - Market Cap (intraday)
235.666M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
75.50 - EPS (TTM)
0.0400 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.50
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
www.protalix.comRecent News: PLX
View MorePerformance Overview: PLX
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PLX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PLX
View MoreValuation Measures
Market Cap
234.10M
Enterprise Value
204.79M
Trailing P/E
75.00
Forward P/E
6.82
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.55
Price/Book (mrq)
5.42
Enterprise Value/Revenue
3.84
Enterprise Value/EBITDA
31.41
Financial Highlights
Profitability and Income Statement
Profit Margin
5.49%
Return on Assets (ttm)
3.10%
Return on Equity (ttm)
7.64%
Revenue (ttm)
53.4M
Net Income Avi to Common (ttm)
2.93M
Diluted EPS (ttm)
0.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
34.83M
Total Debt/Equity (mrq)
12.79%
Levered Free Cash Flow (ttm)
5.43M